Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
Unilateral Pallidotomy for Parkinson's Disease:Comparison of Outcome in Yonger Vs Elderly Patients
Neurol 49:1072-1077, Uitti,R.J.,et al, 1997
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation
JAMA 305:732, Pluta,R.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Parkinson's Disease
Lancet 363:1783-1793, Samii,A.,et al, 2004
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Five-Year Follow-up of Bilateral Stimulatioin of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 349:1925-1934,1888, Krack,P.,et al, 2003
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Surgery for Parkinson Disease
Arch Neurol 57:1118-1125, Lang,A.E., 2000
Multicentre European Study of Thalamic Stimulation in Paarkinsonisn and Essential Tremor
JNNP 66:289-296, Limousin,P.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease
NEJM 341:988-992, Freeman,T.B.,et al, 1999
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Functional Neurosurgery for parkinson's Disease, Has Come a Long Way, Though Much Remains Experimental
BMJ 316:1259-1260, Quinn,N.&Bhatia,K., 1998
Pallidotomy for Parkinson's Disease:Hitting the Target
Lancet 351:998-999, Golbe,L.I., 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998